Progyny, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of Progyny, Inc.'s 2022 Annual Meeting of Stockholders held on May 25, 2022. The filing details the voting outcomes for three specific proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on the following three proposals:
- Proposal 1: Election of Directors - All three Class III director nominees were elected to serve until the 2025 Annual Meeting.
- Dr. Fred E. Cohen: 54,837,777 votes for; 23,959,334 votes withheld.
- Dr. Norman Payson: 47,869,440 votes for; 30,927,631 votes withheld.
- Dr. Beth Seidenberg: 54,866,543 votes for; 23,930,568 votes withheld.
- Proposal 2: Ratification of Auditors - Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes For: 83,431,487
- Votes Against: 252,513
- Abstentions: 43,673
- Proposal 3: Executive Compensation - Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers for the fiscal year ending December 31, 2022.
- Votes For: 77,734,833
- Votes Against: 1,011,237
- Abstentions: 51,041
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes for each proposal.
- Review the detailed Proxy Statement filed on April 14, 2022, for full context on the director nominees and executive compensation plans.
- Confirm the tenure of the newly elected directors, which extends until the 2025 Annual Meeting.
- Note the significant number of votes withheld for Dr. Norman Payson compared to other nominees.